Royalty Pharma Management
Management criteria checks 3/4
Royalty Pharma's CEO is Pablo Legorreta, appointed in Jan 1996, has a tenure of 29.92 years. directly owns 1.06% of the company’s shares, worth $239.44M. The average tenure of the management team and the board of directors is 5 years and 5.5 years respectively.
Key information
Pablo Legorreta
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 29.9yrs |
| CEO ownership | 1.1% |
| Management average tenure | 5yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated
Nov 15Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price
Jul 06
Here's Why We Think Royalty Pharma (NASDAQ:RPRX) Is Well Worth Watching
May 31Royalty Pharma: Delivering Growth With A Positive Story Ahead
Feb 13Subdued Growth No Barrier To Royalty Pharma plc (NASDAQ:RPRX) With Shares Advancing 25%
Jan 29Royalty Pharma: Key Strategic Updates To Be Priced In
Jan 15Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.22
Jan 13Royalty Pharma: Massive Opportunity Ahead
Nov 09Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
Aug 22Royalty Pharma: Busy Putting Capital To Work
Aug 11Royalty Pharma: Solid Start Of The Year, Buy Confirmed
May 11Royalty Pharma: Solid Operational Performance
Feb 19Royalty Pharma: One Of The Best Names In Pharmaceuticals
Jan 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$765m |
| Jun 30 2025 | n/a | n/a | US$1b |
| Mar 31 2025 | n/a | n/a | US$1b |
| Dec 31 2024 | n/a | n/a | US$859m |
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$673m |
| Mar 31 2024 | n/a | n/a | US$799m |
| Dec 31 2023 | n/a | n/a | US$1b |
| Sep 30 2023 | n/a | n/a | US$184m |
| Jun 30 2023 | n/a | n/a | US$255m |
| Mar 31 2023 | n/a | n/a | US$332m |
| Dec 31 2022 | n/a | n/a | US$43m |
| Sep 30 2022 | n/a | n/a | US$507m |
| Jun 30 2022 | n/a | n/a | US$466m |
| Mar 31 2022 | n/a | n/a | US$602m |
| Dec 31 2021 | US$50m | US$8m | US$620m |
| Sep 30 2021 | n/a | n/a | US$783m |
| Jun 30 2021 | n/a | n/a | US$972m |
| Mar 31 2021 | n/a | n/a | US$493m |
| Dec 31 2020 | US$56m | n/a | US$495m |
| Sep 30 2020 | n/a | n/a | US$2b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$29m | n/a | US$2b |
Compensation vs Market: Insufficient data to establish whether Pablo's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Pablo's compensation has been consistent with company performance over the past year.
CEO
Pablo Legorreta (61 yo)
Mr. Pablo Gerardo Legorreta is Principal and Co-Founder of Pharmakon Advisors, LP. He is Trustee of Hospital for Special Surgery. He is Investment Manager of BioPharma Credit PLC.He is Chairman of the Boa...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 29.9yrs | no data | 1.06% $ 239.4m | |
| Executive VP & CFO | no data | US$1.26m | 0.15% $ 32.7m | |
| Vice Chairman & Executive VP | 5.7yrs | US$1.26m | 0.17% $ 38.4m | |
| Executive Vice President of Research & Investments | 5yrs | US$1.26m | 0.030% $ 6.7m | |
| Executive Vice President of Investments & General Counsel | 3.2yrs | no data | no data | |
| Executive Vice President of Investments | 2.7yrs | no data | no data | |
| Senior VP & Chief Technology Officer | 2.3yrs | no data | no data | |
| Executive VP of Investments & Chief Scientific Officer | 5yrs | US$3.40m | no data | |
| Senior VP and Head of Investor Relations & Communications | no data | no data | no data | |
| Executive VP & Head of Human Capital | 1.4yrs | no data | no data | |
| Senior Vice President of Strategy & Analytics | 5yrs | no data | no data |
Experienced Management: RPRX's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 29.9yrs | no data | 1.06% $ 239.4m | |
| Independent Director | 3.5yrs | US$150.00k | 0.0060% $ 1.4m | |
| Director | less than a year | no data | no data | |
| Lead Independent Director | 5.4yrs | US$150.00k | 0.0086% $ 1.9m | |
| Independent Director | 5.5yrs | US$150.00k | 0.015% $ 3.4m | |
| Independent Director | 5.5yrs | US$150.00k | 0.044% $ 9.9m | |
| Independent Director | 5.5yrs | US$150.00k | 0.015% $ 3.4m | |
| Director | less than a year | no data | 0.00075% $ 168.8k | |
| Independent Director | 5.5yrs | US$150.00k | 0.0080% $ 1.8m | |
| Director | less than a year | no data | no data |
Experienced Board: RPRX's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/31 19:26 |
| End of Day Share Price | 2025/12/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Royalty Pharma plc is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Geoffrey Meacham | Citigroup Inc |
| Prem Chulaki | Crisp Idea |